Biopharmaceutical company Catalyst Pharmaceuticals, Inc. (CPRX) develops and commercializes therapies for people with rare debilitating, chronic neuromuscular and neurological diseases. The company’s offerings include Firdapse to treat Lambert-Eaton Myasthenic Syndrome (LEMS) patients.
For the fiscal first quarter (ended March 31, 2023), CPRX’s EPS increased by a robust 117% year-over-year to $0.26. However, it missed the consensus EPS estimate by 19.3%.
